Citius Pharmaceuticals (NASDAQ:CTXR) Earns Hold Rating from D. Boral Capital

D. Boral Capital reaffirmed their hold rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research note issued to investors on Friday morning,Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

NASDAQ:CTXR opened at $0.13 on Friday. Citius Pharmaceuticals has a 1 year low of $0.11 and a 1 year high of $1.07. The stock’s fifty day moving average price is $0.39 and its two-hundred day moving average price is $0.57. The company has a market cap of $24.13 million, a P/E ratio of -0.56 and a beta of 1.66.

Institutional Investors Weigh In On Citius Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC purchased a new position in Citius Pharmaceuticals in the 2nd quarter worth about $5,928,000. Vanguard Group Inc. increased its position in shares of Citius Pharmaceuticals by 1.5% during the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after acquiring an additional 104,889 shares during the period. Arkadios Wealth Advisors raised its stake in shares of Citius Pharmaceuticals by 50.0% during the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock valued at $88,000 after acquiring an additional 50,000 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at approximately $69,000. Finally, Point72 DIFC Ltd bought a new position in Citius Pharmaceuticals in the second quarter worth approximately $29,000. 16.88% of the stock is owned by institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.